The newly created standalone company will be called Astoriom and will allow the company to focus on biorepository as its core growth area, expanding its footprint within high-value pharmaceutical and biologic markets with a buy-and-build growth strategy in the US and European markets.
Limerston Capital are a mid-market private equity house focused on driving value though buy-and-build and operational transformation.
The BDO project team included:
Derek Neil, Lewis Winston, Olivia Wakefield, Amy Bannister, Rebecca Page, Rajat Handa (financial due diligence)
Nicoletta Papademetris, Will Searle, Chris Arbuthnott, Laurence Mills, Linda Moore (Tax)
"Lewis and the BDO Life Sciences team were great to work with, and provided fantastic support over an extended diligence period. Their sector knowledge really shone through and we look forward to working with them again in the future."
Zach Taylor, Investment Principal, Limerston Capital